PMID- 28828622
OWN - NLM
STAT- MEDLINE
DCOM- 20180905
LR  - 20181202
IS  - 1568-5608 (Electronic)
IS  - 0925-4692 (Linking)
VI  - 26
IP  - 2
DP  - 2018 Apr
TI  - Modafinil attenuates inflammation via inhibiting Akt/NF-kappaB pathway in 
      apoE-deficient mouse model of atherosclerosis.
PG  - 385-393
LID - 10.1007/s10787-017-0387-3 [doi]
AB  - Modafinil, an FDA approved wakefulness drug prescribed to narcolepsy patients, 
      has recently been shown to have anti-inflammatory effects and provides protection 
      against neuroinflammation. It is unknown if modafinil can also protect against 
      atherosclerosis, pathogenesis of which implicates inflammation. Using an 
      apoE-deficient mouse model, we tried to elucidate the effects of modafinil 
      treatment on the development of atherosclerosis. We tested serum levels of 
      cytokines. We isolated mouse bone marrow-derived macrophages (BMDMs), detected 
      effect of modafinil on the viability and proliferation of BMDMs, and on oxidized 
      low-density lipoprotein-induced IL-6 and TNF-alpha, and supernatant level of IFN-gamma as 
      well as NF-kappaB activity in BMDMs. Modafinil inhibited the development of 
      atherosclerosis in apoE(-/-) mice. Modafinil suppressed the secretion of 
      pro-inflammatory cytokines IL-6, TNF and IFN-gamma, and promoted secretion of 
      anti-inflammatory cytokines IL-4 and IL-10. Modafinil inhibited viability and 
      proliferation of macrophages by negatively regulating levels of pro-inflammatory 
      cytokines, p-Akt, p-IKBalpha and NF-kappaB activity in macrophages. Modafinil mitigates 
      inflammation in apoE(-/-) atherosclerosis mice via inhibiting NF-kappaB activity in 
      macrophages, and could potentially serve as a therapeutic agent for 
      atherosclerosis.
FAU - Han, Jinxia
AU  - Han J
AUID- ORCID: 0000-0002-1296-8452
AD  - Department of Cardiology, Daqing Oil Field General Hospital, NO. 9 Saertu 
      District, Daqing, 163000, Heilongjiang, China. hanjinxia79@163.com.
FAU - Chen, Dongwei
AU  - Chen D
AD  - Department of Geriatrics, Daqing Longnan Hospital, NO. 35 Patriotic Road, 
      Ranghulu District, Daqing, 163000, Heilongjiang, China.
FAU - Liu, Dayi
AU  - Liu D
AD  - Department of Cardiology, Daqing Oil Field General Hospital, NO. 9 Saertu 
      District, Daqing, 163000, Heilongjiang, China.
FAU - Zhu, Yanan
AU  - Zhu Y
AD  - Department of Cardiology, Daqing Oil Field General Hospital, NO. 9 Saertu 
      District, Daqing, 163000, Heilongjiang, China.
LA  - eng
PT  - Journal Article
DEP - 20170821
PL  - Switzerland
TA  - Inflammopharmacology
JT  - Inflammopharmacology
JID - 9112626
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Apolipoproteins E)
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Cytokines)
RN  - 0 (NF-kappa B)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - R3UK8X3U3D (Modafinil)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/pharmacology
MH  - Apolipoproteins E/*metabolism
MH  - Atherosclerosis/*drug therapy/metabolism
MH  - Benzhydryl Compounds/*pharmacology
MH  - Cell Proliferation/drug effects
MH  - Cytokines/metabolism
MH  - Disease Models, Animal
MH  - Inflammation/*drug therapy/metabolism
MH  - Macrophages/drug effects
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Modafinil
MH  - NF-kappa B/*metabolism
MH  - Proto-Oncogene Proteins c-akt/*metabolism
MH  - Signal Transduction/drug effects
OTO - NOTNLM
OT  - Atherosclerosis
OT  - Inflammation
OT  - Modafinil
OT  - NF-kappaB
OT  - apoE
EDAT- 2017/08/23 06:00
MHDA- 2018/09/06 06:00
CRDT- 2017/08/23 06:00
PHST- 2017/05/24 00:00 [received]
PHST- 2017/08/03 00:00 [accepted]
PHST- 2017/08/23 06:00 [pubmed]
PHST- 2018/09/06 06:00 [medline]
PHST- 2017/08/23 06:00 [entrez]
AID - 10.1007/s10787-017-0387-3 [pii]
AID - 10.1007/s10787-017-0387-3 [doi]
PST - ppublish
SO  - Inflammopharmacology. 2018 Apr;26(2):385-393. doi: 10.1007/s10787-017-0387-3. 
      Epub 2017 Aug 21.